Payment overview · 2025
General Payments
$2,520.42
157 reported records · 17 companies
Healthcare provider profile · identity verified
Haitham Jifi-Bahlool, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CORPUS CHRISTI, TX · NPI 1063447514
Verified facts
What the public records show
CMS Open Payments records show Haitham Jifi-Bahlool, MD received $2,520.42 in general payments during 2025 across 157 reported records.
Novo Nordisk Inc accounted for 25.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Kerendia, Linzess, Mounjaro, Ozempic, Paxlovid, Rybelsus, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vraylar by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 170 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 284 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $649.20 | 25.8% | 30 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $431.09 | 17.1% | 14 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $387.96 | 15.4% | 46 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $262.85 | 10.4% | 12 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $208.81 | 8.3% | 15 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$157.54 | 6.2% | 18 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $71.09 | 2.8% | 4 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $52.75 | 2.1% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $51.47 | 2.0% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $48.79 | 1.9% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $43.54 | 1.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $43.36 | 1.7% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $33.33 | 1.3% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $24.91 | 1.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $22.28 | 0.9% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $16.21 | 0.6% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.24 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,520.42 | 157 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $555.83 | 25 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $431.09 | 14 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $230.20 | 28 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $220.06 | 27 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $208.81 | 15 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $200.81 | 13 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $187.60 | 14 | 2025 |
Source payment records
|
|||||
| SYNCHROMEDII Normalized: synchromedii |
Device | Medtronic, Inc. | $157.54 | 18 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $141.01 | 11 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $131.02 | 10 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $121.84 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $93.37 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $76.87 | 9 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $63.52 | 8 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $52.75 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $51.47 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $48.79 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $44.10 | 6 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $43.54 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $43.36 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $40.65 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $40.65 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $33.33 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $30.44 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $24.91 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $22.28 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $17.37 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $16.21 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $15.24 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $13.67 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $13.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 54 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 25 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 142 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 284 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 12 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 40 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 31 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
25 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
31 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
170 | 55 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
142 | 41 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
57 | 20 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
284 | 76 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
40 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
54 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1079 | 132 |
| Atorvastatin Calcium | Atorvastatin Calcium | 853 | 336 |
| Levothyroxine Sodium | Levothyroxine Sodium | 483 | 174 |
| Amlodipine Besylate | Amlodipine Besylate | 482 | 181 |
| Lisinopril | Lisinopril | 477 | 184 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 403 | 145 |
| Losartan Potassium | Losartan Potassium | 401 | 149 |
| Gabapentin | Gabapentin | 381 | 127 |
| Metformin Hcl | Metformin Hcl | 355 | 150 |
| Zolpidem Tartrate | Zolpidem Tartrate | 294 | 49 |
| Omeprazole | Omeprazole | 292 | 106 |
| Ozempic | Semaglutide | 284 | 76 |
| Alprazolam | Alprazolam | 266 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 260 | 96 |
| Pantoprazole Sodium | Pantoprazole Sodium | 233 | 81 |
| Hydrochlorothiazide | Hydrochlorothiazide | 213 | 94 |
| Tamsulosin Hcl | Tamsulosin Hcl | 185 | 61 |
| Tramadol Hcl | Tramadol Hcl | 185 | 61 |
| Jardiance | Empagliflozin | 170 | 55 |
| Montelukast Sodium | Montelukast Sodium | 162 | 61 |
| Clopidogrel | Clopidogrel Bisulfate | 159 | 66 |
| Sertraline Hcl | Sertraline Hcl | 158 | 57 |
| Pioglitazone Hcl | Pioglitazone Hcl | 149 | 60 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 148 | 70 |
| Duloxetine Hcl | Duloxetine Hcl | 145 | 44 |
| Furosemide | Furosemide | 143 | 53 |
| Mounjaro | Tirzepatide | 142 | 41 |
| Famotidine | Famotidine | 140 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 137 | 51 |
| Pregabalin | Pregabalin | 121 | 32 |
| Trazodone Hcl | Trazodone Hcl | 121 | 46 |
| Simvastatin | Simvastatin | 119 | 47 |
| Farxiga | Dapagliflozin Propanediol | 116 | 36 |
| Clonazepam | Clonazepam | 106 | 23 |
| Azithromycin | Azithromycin | 105 | 85 |
| Tizanidine Hcl | Tizanidine Hcl | 104 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 103 | 40 |
| Ezetimibe | Ezetimibe | 101 | 43 |
| Glipizide | Glipizide | 101 | 39 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 92 | 33 |
| Ibuprofen | Ibuprofen | 89 | 22 |
| Alendronate Sodium | Alendronate Sodium | 87 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 84 | 38 |
| Donepezil Hcl | Donepezil Hcl | 81 | 24 |
| Allopurinol | Allopurinol | 79 | 30 |
| Potassium Chloride | Potassium Chloride | 78 | 29 |
| Carvedilol | Carvedilol | 76 | 33 |
| Hydralazine Hcl | Hydralazine Hcl | 76 | 36 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 73 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 72 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 72 | 36 |
| Metformin Hcl Er | Metformin Hcl | 70 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 65 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 64 | 22 |
| Lorazepam | Lorazepam | 63 | 14 |
| Valsartan | Valsartan | 63 | 27 |
| Buspirone Hcl | Buspirone Hcl | 62 | 20 |
| Myrbetriq | Mirabegron | 62 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 61 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 59 | 57 |
| Meclizine Hcl | Meclizine Hcl | 59 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 58 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | 19 |
| Trulicity | Dulaglutide | 57 | 20 |
| Labetalol Hcl | Labetalol Hcl | 56 | 13 |
| Celecoxib | Celecoxib | 55 | 25 |
| Eliquis | Apixaban | 54 | 24 |
| Meloxicam | Meloxicam | 51 | 22 |
| Finasteride | Finasteride | 46 | 18 |
| Methylprednisolone | Methylprednisolone | 46 | 40 |
| Fenofibrate | Fenofibrate Nanocrystallized | 45 | 16 |
| Ondansetron Odt | Ondansetron | 45 | 17 |
| Prednisone | Prednisone | 45 | 20 |
| Benazepril Hcl | Benazepril Hcl | 44 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 43 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | 12 |
| Lovastatin | Lovastatin | 42 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 42 | 14 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 41 | suppressed |
| Baclofen | Baclofen | 40 | 11 |
| Fenofibrate | Fenofibrate | 40 | 19 |
| Rybelsus | Semaglutide | 40 | 11 |
| Spironolactone | Spironolactone | 40 | 19 |
| Clonidine Hcl | Clonidine Hcl | 38 | 19 |
| Diazepam | Diazepam | 38 | 14 |
| Lidocaine | Lidocaine | 37 | 12 |
| Nystatin | Nystatin | 37 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 35 | 12 |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 17 |
| Topiramate | Topiramate | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 32 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 30 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 30 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | 11 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 29 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | 12 |
| Nitroglycerin | Nitroglycerin | 27 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Glimepiride | Glimepiride | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | 13 |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Linzess | Linaclotide | 25 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | 19 |
| Ramipril | Ramipril | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 19 |
| Digoxin | Digoxin | 23 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 23 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 22 | suppressed |
| Naproxen | Naproxen | 22 | 11 |
| Promethazine Hcl | Promethazine Hcl | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 11 |
| Eszopiclone | Eszopiclone | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 17 |
| Telmisartan | Telmisartan | 21 | suppressed |
| Vascepa | Icosapent Ethyl | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 19 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 13 |
| Irbesartan | Irbesartan | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Clotrimazole | Clotrimazole | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Kerendia | Finerenone | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Livalo | Pitavastatin Calcium | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 11 |
| Colchicine | Colchicine | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 11 |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,520.42 · 157 records | Novo Nordisk Inc | ACCRUFER, AREXVY, Auvelity, BOTOX, CAPLYTA, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, GEMTESA, KRYSTEXXA, Kerendia, Korlym, LEQVIO, LINZESS, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, QULIPTA, REPATHA, Rybelsus, SHINGRIX, SYNCHROMEDII, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Wegovy, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error